Fecal microbiota transplantation for patients with irritable bowel syndrome

A meta-analysis protocol

Wenting Wen, MD, Haibo Zhang, MD, Junlong Shen, PhD*, Luxia Wei, PhD, Shunong Shen, PhD*

Abstract

Irritable bowel syndrome (IBS) is a common functional bowel disease characterized by chronic or recurrent abdominal pain, bloating, constipation, and diarrhea. Many patients with IBS have a poor quality of life due to abdominal discomfort, diarrhea, constipation, and the presence of other diseases. At present, intestinal motility inhibitors, adsorbents, astringents, intestinal mucosal protective agents, and antidepressants have been combined to treat IBS, but the treatment process is long, which results in a large economic burden to patients. Fecal microbiota transplantation (FMT) is a treatment involving the transplantation of functional bacteria from healthy human feces into the gastrointestinal tract of patients; thus, replacing the intestinal flora and modulating intestinal and extra-intestinal diseases. In recent years, the efficacy and economic benefits of FMT in the treatment of IBS have received increasing attention from researchers.

A search for randomized controlled trials (RCTs) on treating IBS with FMT will be performed using 9 databases, including PubMed, the Cochrane Library, Embase, ClinicalTrials, China National Knowledge Infrastructure, Sino Med, ScienceDirect, VIP, and Wanfang Data. Two reviewers will independently screen data extraction studies and assess study quality and risk of bias. The risk of bias for each RCT will be assessed against the Cochrane Handbook standards to ascertain methodological quality. RevMan V.5.3 software will be used to calculate data synthesis when meta-analysis is allowed.

This study will provide a high-quality synthesis of existing evidence on the effectiveness and safety of FMT in the treatment of IBS. This study will determine if FMT is an effective and safe intervention for IBS.

PROSPERO registration number is PROSPERO CRD42018108080.

Abbreviations: CIs = confidence intervals, FMT = fecal microbiota transplantation, IBS = irritable bowel syndrome, RCTs = randomized controlled trials.

Keywords: fecal microbiota transplantation, irritable bowel syndrome, meta-analysis, protocol

1. Introduction

Irritable bowel syndrome (IBS) is a chronic, recurrent functional gastrointestinal disorder,[1] characterized by changes in bowel habits or stool features, continuous or intermittent abdominal pain, and bloating or abdominal discomfort,[2] with a prevalence of up to 10% to 20% in the United Kingdom and the United States[3,4] and a prevalence of 5% to 10% in most Asian countries.[5,6] Recent studies show that the prevalence of IBS in Asian and African regions increases as the economy grows.[3,4] There are a number of factors to be involved in the pathogenesis of IBS, including impaired motility and sensitivity, increased permeability, changes in the gut microbiome, and alterations in the brain–gut axis.[7,8] The first presentation of IBS patient to a physician is mostly between the age of 30 and 50 years, and the symptoms’ onset is closely related to psychological stress.[3] Individuals with IBS have a 2-fold higher risk of comorbid depression, anxiety, and sleep disorders. Conversely, 25% to 30% of patients with depression and 10% to 45% of patients with anxiety are reported to develop IBS.[9–11] The coexistence of chronic disease with psychiatric disorder can be a big burden, and comorbid depression has a stronger negative effect on health than depression or anxiety does alone.[12] As measured by validated survey instruments, such as the Short Form-36, IBS has a negative impact on an affected patient’s quality of life.[13] Annually, IBS costs the US health system in excess of $30 billion.[14] In recent years, combined administration of intestinal peristalsis inhibitors, adsorbents, astringents, intestinal mucosa protectors, and antidepressants in the treatment of IBS have achieved a certain therapeutic effect, but with a long therapeutic course and heavy economic burden for the patient, and with a high recurrence rate after ceasing the drugs.[15] Therefore, the most urgent and intractable problem...
for clinical gastroenterologists to deal with is to develop a both effective and economical treatment method that could cope with different symptoms of IBS.\(^{116}\)

Fecal microbiota transplantation (FMT), also known as a stool transplant, is the transplantation of fecal bacteria from a healthy individual into a recipient, often with the intent to cure intestine-associated diseases by rebuilding the intestinal microbial community structure.\(^{17}\) In ancient China, feces were commonly used to treat diseases. Published clinical trials and systematic evaluations support a positive role for FMT in treating inflammatory bowel disease.\(^{18}\) In recent years, researchers have begun to look to treating IBS with FMT, with an increasing number of trials having been published on the subject. The purpose of this meta-analysis is to systematically evaluate the efficacy and safety of FMT in the treatment of IBS and to provide recommendations for experimental research on clinical application of FMT in IBS.

2. Methods

2.1. Inclusion criteria for study selection

2.1.1. Types of studies. All randomized controlled trials (RCTs) will be included without language limitations.

2.1.2. Types of participants. Standard diagnosis of IBS patients will be included in the analysis, regardless of their age, gender, ethnicity, and background, according to the Manning and Rome I, II, III, and IV criteria.

2.1.3. Types of interventions. In this study, the intervention received by patients with IBS in the experimental group will be fecal bacteria transplantation, while the control group will be administered a placebo.

2.1.4. Result measurements. The main outcome assessed will be change in the symptom scores of patients with IBS after treatment compared to that before treatment, while the secondary outcomes measured will be changes in anxiety and depression symptoms and quality of life.

2.2. Retrieval strategy

2.2.1. Electronic searches. To identify relevant information, the PubMed, Cochrane Library, Embase, ClinicalTrials, China National Knowledge Infrastructure, Sino Med, ScienceDirect, VIP, and Wanfang Data databases will be electronically searched. All the databases will be searched from their inception to March 1, 2019. No language restrictions will be applied to the search.

2.3. Data collection and analysis

2.3.1. Selection of studies. Two reviewers (WW and HZ) will independently search and evaluate every relevant study according to the Cochrane Handbook for Systematic Reviews of Interventions and perform the following:

1. eliminate irrelevant literature based on titles and abstracts,
2. organize the article results using NoteExpress software and eliminate any duplicates,
3. eliminate nonconforming literature based on the inclusion criteria by perusing the full text, and
4. amalgamating all literature that reports on identical clinical studies.

The selection process will be summarized according to the PRISMA flow diagram. The 2 reviewers will review the full text of these studies according to the standardized eligibility criteria to assess their qualifications. Detailed reasons for cancellation of the trial will be recorded when screening papers. Any differences will be resolved through discussions between the 2 reviewers. If no consensus is reached during the discussion, an independent reviewer will be consulted.

2.3.2. Data extraction and management. Data from each selected article will be extracted independently by WW and HZ. The general research information will include patient characteristics (gender, mean age, and mean duration of disease), diagnostic criteria (Rome I, II, III, or IV or Manning), interventions received by the experimental and control groups, and major and minor events. A third researcher, JS, will re-examine the data. If necessary, we will consult the author of the article for more information. Any possible differences will be resolved by arbitrators and experts.

2.3.3. Processing missing data. When experimental data are missing or inadequate, we will attempt to contact the original author of the study by e-mail or telephone to obtain sufficient and comprehensive data. Incomplete data will be discarded if sufficient data cannot be retrieved.

2.3.4. Assessment of risk of bias in included studies. Two reviewers (WW and HZ) will independently evaluate the risk of bias in the eligible studies using the Cochrane Collaboration’s tool. Each study will be evaluated for validity based on the following 7 aspects: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete data assessment, selective outcome reporting, and other sources of bias, according to the Cochrane risk of bias standards.

2.3.5. Heterogeneity assessment and statistical analysis. Review Manager 5.3 software will be utilized for statistical analysis on the basis of homogeneity of the included trials. Odds ratios and 95% confidence intervals (95% CIs) will be applied for dichotomous data; continuous data, weighted mean differences, and 95% CIs for analysis when units are the same, while standardized mean differences and 95% CIs will be used for analysis when units are different. The \(I^2\) statistic will be utilized for assessing the heterogeneity of the included trials. A fixed effects model will be applied to calculate the pooled statistics in the absence of substantial heterogeneity (\(I^2 < 50\%\) and \(P \geq 0.1\)). Conversely, if statistical heterogeneity is identified (\(I^2 > 50\%\) or \(P < 0.1\)), the causes of the heterogeneity will be identified first by subgroup analysis. If the heterogeneity cannot be readily explained, a random effects model will be interpreted with caution.
2.3.6. **Subgroup analysis.** If significant heterogeneity is observed in the included studies, subgroup analysis will be performed based on age, gender, interventions, controls, and outcome measurements.

2.3.7. **Assessment of reporting biases.** If there are sufficient number of articles (>10) included under the same endpoint addressing the same question, a funnel plot will be used to measure publication bias.

2.3.8. **Sensitivity analysis.** If sufficient test data are available, sensitivity analysis will be performed to determine whether the conclusion is robust.

2.3.9. **Grading of quality of evidence.** The Grading of Recommendations Assessment, Development, and Evaluation evaluation will be utilized for assessing the quality of evidence for the main outcomes. The quality of evidence will be categorized as high, moderate, low, or very low.

2.3.10. **Ethics and dissemination.** Ethics approval is not required because the data will not include individual patient data and, therefore, will not incur raise any privacy issues. The results of this systematic review will be disseminated only in a peer-reviewed publication.

3. **Discussion**

IBS is a functional disorder of the gastrointestinal tract and its physiology is not very well-understood. Published studies confirm an association between IBS and disorders of the intestinal flora. The ideal composition of a healthy microbiome has not yet been defined, but the composition of the fecal microbiota in patients with IBS differs significantly from that in healthy controls, with several differences in bacterial species having been identified. Studies have shown that probiotic supplementation aids in the treatment of IBS, but high-quality studies tend to indicate a less notable therapeutic effect, and the compositions of probiotic supplements vary greatly.

In recent years, FMT has attracted considerable attention for treatment of gastrointestinal microbe-related diseases. FMT has great potential to become a highly effective, low-cost treatment for IBS. The intestinal flora in fecal microbiota originates from healthy people, ensuring the diversity of the probiotics. An increasing number of RCTs have been published in clinical studies and, therefore, we will conduct this systematic review and meta-analysis to assess the efficacy and safety of FMT in the treatment of IBS.

To the best of our knowledge, this is the first analysis of the literature on the use of FMT to treat IBS. We hope this systematic review will provide strong evidence for the efficacy and safety of FMT in treating IBS, to be used by clinicians, researchers, and health-policy advisors.

**Author contributions**

**Conceptualization:** Wenting Wen, Haibo Zhang, Junlong Shen and Shunong Shen

**Data curation:** Wenting Wen and Haibo Zhang

**Formal analysis:** Wenting Wen, Haibo Zhang, and Junlong Shen

**Writing:** Wenting Wen, Haibo Zhang, and Luxia Wei

**Funding acquisition:** Junlong Shen, Luxia Wei, and Wenting Wen

**Wenting Wen orcid:** 0000-0002-3930-818X

---

**References**

[1] Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480–91.

[2] Drossman DA, Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders. J Gastrointest Liver Dis 2006;15:237–41.

[3] Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108–31.

[4] Chang FY, Lu CL. Irritable bowel syndrome in the 21st century: perspectives from Asia or South-east Asia. J Gastroenterol Hepatol 2007;22:4–12.

[5] Aziz Q, Thompson DG. Brain-gut axis in health and disease. Gastroenterology 1998;114:559–78.

[6] Kusano M, Sekiguchi T, Kawamura O, et al. Further classification of dysmotility-like dyspepsia by interdigestive gastro-duodenal manometry and plasma motilin level. Am J Gastroenterol 1997;92:481–4.

[7] Zhong L, Hou X. Pathobiophysiologic findings of irritable bowel syndrome in China. J Neurogastroenterol Motil 2012;18:19–33.

[8] Surde-Blaga T, Bilban A, Dumitrascu DL. Psychosocial determinants of irritable bowel syndrome. World J Gastroenterol 2012;18:616–26.

[9] Lee YT, Hu LY, Shen CC, et al. Risk of psychiatric disorders following irritable bowel syndrome: a nationwide population-based cohort study. PLoS One 2015;10:e0133283. Article e0133283.

[10] Pinto-Sánchez MJ, Ford AC, Avila CA, et al. Anxiety and depression increase in a stepwise manner in parallel with multiple FGIIs and symptom severity and frequency. Am J Gastroenterol 2015;110:1038–48.

[11] Sibelli A, Chalder T, Everitt H, et al. A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset. Psychol Med 2016;46:3065–80.

[12] Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:833–48.

[13] Granulek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:634–60.

[14] Lembo AJ. The clinical and economic burden of irritable bowel syndrome. Pract Gastroenterol 2007;31:3–9.

[15] Zhang CX, Guo L, Wang YY, et al. Electroacupuncture combined with Qbizi mixture for diarrhea-predominant irritable bowel syndrome: a randomized controlled trial. World J Acupunct Moxib 2018;28:19–24.

[16] Shu Y, Chen YH, Yin XJ, et al. Electroacupuncture versus moxibustion for irritable bowel syndrome: a randomized, parallel-controlled trial. Evid Based Complement Altern Med 2015;2015: Article ID 361786.

[17] Li XX, Hu XM, Zhang DW. Advance in research on fecal microbiota transplantation and therapy in inflammatory bowel disease. Chin J Gastroenterol Hepatol 2018;27:220–3.

[18] Bouri S, Hart A. Fecal microbial transplantation: an update. Curr Opin Clin Nutr Metab Care 2018;21:405–10.

[19] Salem AE, Singh R, Ayoub YK. The gut microbiome and irritable bowel syndrome: state of art review. Arab J Gastroenterol 2018;18:30021–2.

[20] Dave M, Higgins PD, Middha S. The human gut microbiome: current knowledge, challenges, and future directions. Transl Res 2012;160:246–57.

[21] Malikowski T, Khanna S, Kadir DS. Fecal microbiota transplantation for gastrointestinal disorders. Curr Opin Gastroenterol 2017;33:8–13.

[22] Sundin J, Ohman L, Simren M. Understanding the gut microbiota in inflammatory and functional gastrointestinal diseases. Psychosom Med 2017;79:657–67.

[23] Sundin J, Rangel I, Fuentes S, et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther 2018;41:342–51.

[24] Ohman L, Tornblom H, Simren M. Crosstalk at the mucosal border: importance of the gut microbiome in IBS. Nat Rev Gastroenterol Hepatol 2015;12:36–49.

[25] Kassinen A, Krogas-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24–33.

[26] Malinen E, Rintila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2003;100:373–82.

[27] Matoj M, Mauunkela L, Kajander K, et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome—a longitudinal study in IBS and control subjects. PEMS Immunol Med Microbiol 2005;43:213–22.
Balsari A, Ceccarelli A, Dubini F, et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982;5:185–94. [PubMed], [Web of Science®], [Google Scholar].

Si JM, Yu YC, Fan YJ, et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004;10:1802–5.

Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009;15:2887–92.

Codling C, O’Mahony L, Shanahan F, et al. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010;55:392–7.

Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011;141:1792–801.

Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 2012;24:31–9.

Parkes GC, Brostoff J, Whelan K, et al. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 2008;103:1557–67.

Rajilic-Stojanovic M, Jonkers DM, Salonen A, et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol 2015;110:278–87.

Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015;313:949–58.